ArticleNeuroepidemiology2022
Descriptive Epidemiology of Neurodegenerative Diseases: What Are the Critical Questions?
Article in Neuroepidemiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Review
- Prostaglandins: Key players in immunomodulation of the nervous system.Neural regeneration research · 2026Article
- Targeting Neuroinflammation and Oxidative Stress to Slow Neurodegeneration in the Visual System.Journal of clinical medicine · 2026Review
- Dissecting genetic variant contributions to neurodegenerative disorders through targeted gene sequencing in a Sicilian population.Scientific reports · 2026Article
- Low Sensitivity of Neuropsychological Scales Hinder Detection of Potential Benefit of Treatments in Alzheimer's Disease: A Position Paper.European journal of neurology · 2026Review
- Cellular Senescence in Neurodegeneration: From Cell Types to Therapeutic Opportunities.Biomedicines · 2026Review
- Antioxidant and Neuroprotective Potential of Some Edible Fruits and Vegetable Extracts Based on Comparative Phytochemical Profiling and Bioactivity.Plants (Basel, Switzerland) · 2026Article
- Classifying drug-related problems of neurodegenerative diseases in the physician-pharmacist joint clinic of neurology: an application of the PCNE method.BMC geriatrics · 2026Article
- Exploring Neurodegenerative Diseases: Bridging the Gap betweenCurrent pharmaceutical design · 2026Review
- Benefits of virtual reality rehabilitation on neurodegenerative diseases: a systematic review.NPJ digital medicine · 2025Article
- Brain Organoids in Neurodegenerative Disease Modeling: Advances, Applications and Future Perspectives.Molecular neurobiology · 2025Review
- NGS Approaches in Clinical Diagnostics: From Workflow to Disease-Specific Applications.International journal of molecular sciences · 2025Review
- Heterogeneity of frequencies of motor neuron disease across ethnicities and geographical areas: focus on Arabic countries in the Mediterranean area.Current opinion in neurology · 2025Review
- Underdetection of neurocognitive disorders in Southern Italy: Evidence from the Salento region.The journal of prevention of Alzheimer's disease · 2025Article
- Public hesitancy for AI-based detection of neurodegenerative diseases in France.Scientific reports · 2025Article
- Exploring the Causal Association Between 91 Circulating Inflammatory Proteins and Neurodegenerative Diseases: A Bidirectional Two-Sample Mendelian Randomization and Bioinformatics Analysis.Brain and behavior · 2025Article
- Review
- Striatal dopaminergic patterns and clinical features in frontotemporal dementia.Brain communications · 2025Article
- Assessing the impact of sex and circadian rhythms on rodent behavior: refining preclinical study designs.Einstein (Sao Paulo, Brazil) · 2025Article
- Clinical characteristics and economic burden of Alzheimer's disease inpatients in Hubei Province, China: a retrospective analysis of hospitalization costs and length of stay.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The field of neurodegenerative diseases is a major challenge faced by public health and is still in need of robust preventive measures and disease-modifying treatments. Population-based studies can offer the framework in the context of primary and secondary prevention of neurodegenerative diseases. The epidemiology of neurodegenerative disorders in the last decades has focused on descriptive studies mainly based on the use of clinical criteria. However, clinical definition is basically insufficient both to well-characterize different phenotypes and to make an early diagnosis. Descriptive epidemiology needs a new framework to update the area of neurodegenerative research, based on the advancement of both clinical and biological diagnostic criteria and the urgency for an early diagnosis of the disease. In here, we address the present and future of population-based studies in neurodegenerative disorders and discuss the shift of paradigms in the diagnosis of disease and disease definition. We further debate the changes in biomarker implementation models and type of biomarkers used in population-based studies. Descriptive epidemiology of neurodegenerative disorders is rapidly evolving. These implementations will improve the future design and outcome of population-based studies and policy-making in public health intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.